Etomidate

Etomidate (USAN, INN, BAN; marketed as Amidate) is a short-acting intravenous anaesthetic agent used for the induction of general anaesthesia and sedation for short procedures such as reduction of dislocated joints, tracheal intubation, cardioversion and electroconvulsive therapy. It was developed at Janssen Pharmaceutica in 1964 and was introduced as an intravenous agent in 1972 in Europe and in 1983 in the United States.

Etomidate
(R)-etomidate ethyl ester
Clinical data
Trade namesAmidate, Hypnomidate, Tomvi
AHFS/Drugs.comMonograph
License data
Routes of
administration		Intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding76%
MetabolismEster hydrolysis in plasma and liver
Elimination half-life75 minutes
ExcretionUrine (85%) and Bile duct (15%)
Identifiers
  • Ethyl 3-[(1R)-1-phenylethyl]imidazole-5-carboxylate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.046.700
Chemical and physical data
FormulaC14H16N2O2
Molar mass244.294 g·mol−1
3D model (JSmol)
Melting point67 °C (153 °F)
Boiling point392 °C (738 °F)
  • O=C(OCC)c1cncn1C(c2ccccc2)C
  • InChI=1S/C14H16N2O2/c1-3-18-14(17)13-9-15-10-16(13)11(2)12-7-5-4-6-8-12/h4-11H,3H2,1-2H3 Y
  • Key:NPUKDXXFDDZOKR-UHFFFAOYSA-N Y
  (verify)

The most common side effects include venous pain on injection and skeletal muscle movements.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.